Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amplia Therapeutics ( (AU:ATX) ) has issued an announcement.
Amplia Therapeutics has opened two new U.S. clinical sites at the University of California, Irvine and The Cleveland Clinic for its AMPLICITY trial, which evaluates lead FAK inhibitor narmafotinib in combination with modified FOLFIRINOX in newly diagnosed advanced pancreatic cancer patients. These centres join two existing Australian sites, with three more U.S. sites expected to come online shortly, significantly broadening the recruitment base and strengthening Amplia’s clinical and investor presence in the U.S. market.
The AMPLICITY trial, run under an open IND with the FDA and aligned with Project Optimus principles, will assess safety, tolerability, pharmacokinetics and efficacy across two parts to determine the optimal daily dose of narmafotinib for future studies. The expansion builds on earlier ACCENT trial data, where narmafotinib combined with gemcitabine and Abraxane achieved a higher confirmed response rate and encouraging progression-free survival, underscoring the drug’s potential to enhance standard chemotherapy in pancreatic cancer and raising the stakes for stakeholders watching Amplia’s progress in this high‑need indication.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics is an Australian pharmaceutical company developing a pipeline of Focal Adhesion Kinase inhibitors targeting cancer and fibrosis. Its lead candidate, narmafotinib (AMP945), is being advanced particularly in fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 659,301
Technical Sentiment Signal: Sell
Current Market Cap: A$61.57M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.